ORLANDO (EGMN) - KRAS tumor status has emerged as an important biomarker for the success or failure of therapies for metastatic colorectal cancer and should be assessed before starting treatment, researchers said at a meeting on gastrointestinal cancers sponsored by the American Society of Clinical Oncology."Clinicians should definitely start checking for KRAS status in their patients with advanced colorectal cancer. Such testing will become very easy to do in the next few months," Dr. Josep Tabernero,...